What The Inflation Reduction Act’s Reforms To Medicare Part D Mean For Prescription Drug Prices

Back to Resources
ATINews
01/26/2023
AUTHOR – ATI Advisory

Anna Kaltenboeck recently penned a Health Affairs article that explains how the Inflation Reduction Act will affect Medicare Part D and prescription drug pricing.

Recent News

News

With MA Cuts Coming, Home Care Supplemental Benefits Hang In The Balance

Anne Tumlinson foresees a benefit-offering slowdown in Medicare Advantage with a caveat in a discussion with Home Health Care News,
Read More Read More
News

As US Begins to Tackle High Drug Prices, Congress Gets in the Way

Anna Kaltenboeck writes in Bloomberg Law that Protecting Health Care for All Patients Act legislation would complicate efforts to lower drug prices in the U.S. and undermine Medicare’s new negotiating authority if the bill becomes law.
Read More Read More
News

Drugmaker Data, Price Negotiation Timeline Tee Up Fight With HHS

Anna Kaltenboeck discusses how the Centers for Medicare and Medicaid Services is preparing for prescription drug pricing negotiation with manufacturers with the Inflation Reduction Act now in place.
Read More Read More
Share
LinkedIn / /